Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Bone Miner Res
Hoofdauteurs: Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2019
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916366/
https://ncbi.nlm.nih.gov/pubmed/31411768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3848
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items